 Home > Active Ingredient News > Drugs Articles > More than ten important personnel changes in the medical industry in October! Involving Merck, Novartis, GSK, Hengrui, Roche Diagnostics, etc

More than ten important personnel changes in the medical industry in October! Involving Merck, Novartis, GSK, Hengrui, Roche Diagnostics, etc

 Last Update: 2022-11-15
 Source: Internet
 Author: User

Tags

victor equipment company

cbt company

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

According to incomplete statistics from GBI, in October 2022, there were more than 10 important personnel changes
between MNC and local pharmaceutical companies.
Attracting much attention from the industry include Tian Yu leaving Merck to return to his old club Novartis, Hengrui deputy general manager joining Qilu, GSK vaccine and global health president leaving, and former Daiichi Sankyo executives joining local pharmaceutical companies
.
In addition, Siemens Healthineers announced the restructuring of the Asia-Pacific organization and related personnel appointments, and the resignation
of two senior executives of domestic pharmaceutical companies.

GBI Merck Nova Hengrui Qilu GSK Siemens Healthineers

October Important personnel changes for MNC

Tian Yu left Merck and returned to Novartis

Tian Yu, head of Merck's China Oncology Business Unit, left his post, and at the same time, Merck announced the appointment of Brecht Vanneste takes over as Head of Merck China's Oncology Business Unit, who will be based in Shanghai and report directly to Anna
Tian, President of Merck China.
Tian Yu will join Novartis from November 10 as the head of immunotherapy at Novartis Innovative Drugs China, and become a member of the management team of Novartis Innovative Drugs China, based in Shanghai, reporting directly to Zhang Ying
, President of Novartis Innovative Drugs China.

Tian Yu Brecht Vanneste

Yan Qiong left Novartis to become CEO of Menarini China

Yan Qiong, head of immunotherapy at Novartis Innovative Drugs China, left Novartis on October 31
, 2022.
Previously, GBI reported that on June 1, the organizational structure of Novartis Innovative Drugs China came into effect, and Yan Qiong was appointed as the head of immunotherapy field of
Novartis Innovative Drugs China.
After leaving Novartis, Yan Qiong has been CEO of Menarini China since November 1, and she will be based in Shanghai and report directly to Maurizio, CEO of Menarini Asia-Pacific Luongo
。

Yan Qiong GBI

Roche Diagnostics CEO confirmed

The Roche Group announces the appointment of Matt Sause, current Head of Roche Diagnostics North America, as CEO of Roche Diagnostics and a member of the company's Executive Committee
.
It is reported that Matt Sause joined Roche USA in 2002 as Senior Molecular Account Manager
.
Since then, he has held key leadership positions
in Roche's diagnostics and pharmaceutical businesses in a number of countries, including Japan, Ireland, Peru and South Korea.

Matt Sause

Merck CEO succeeds Furvitzer as Chairman of the Board

Merck's official website announced that the company's current CEO, Robert M.
Davis, will replace Kenneth C.
Frazier) serves as Chairman of the Board effective December 1
, 2022.
The former Chairman of the Board of Directors Fowitzer will officially retire
on November 30, 2022.

GSK's President of Vaccines and Global Health is leaving

According to foreign media, Roger Connor, president of GSK vaccines and global health, will leave
.
Roger With 25 years of experience in vaccines, Connor was appointed President of GSK Vaccines in 2018 and led GSK's Global Health organisation and Global Sourcing organisation
in 2021.
He was also responsible for GSK's global pharmaceutical and consumer healthcare manufacturing organisation
between 2013 and 2018.

Siemens Healthineers reorganizes its organizational structure in Asia Pacific

Siemens Healthineers announced that it will divide the former Asia Pacific region into China and Asia Pacific (including Japan) excluding China, which is still led by Wang Hao, and the newly established Asia Pacific region (including Japan) is headed by former Vy Vy former Chief Compliance and Quality Officer of Varian Tran is responsible
.
Vy Tran joined Varian (now part of Siemens Healthineers) in 1998 and has held leadership positions
in regulatory, quality control, and compliance.
Hao Wang joined Siemens Healthineers in 2001 and worked in marketing and sales, and was later promoted to general manager of
diagnostic imaging and clinical therapy.
After a stint of leadership roles in China at Solin and Philips, Hao returned to Siemens Healthineers
in 2018.

Wang Hao Vy Tran

In October, important personnel changes in local pharmaceutical companies

Former Daiichi Sankyo executives joined Yingen Biotech

Yingen Biologics announces the appointment of Antoine Dr.
Yver is Chairman of
the Company's Scientific Advisory Board.
He will provide advice and guidance to the company's R&D and pipeline development, further enhancing the company's innovative position
in the field of antibody conjugate drugs (ADCs).
Antoine Dr.
Yver is a pediatric oncologist with over 32 years of global pharmaceutical R&D and clinical experience, where he served as Executive Vice President, President and Global Head of Oncology R&D, and Chairman of
the Cancer Business Unit.

SygaGenomics appoints Chief Translational Science Officer

On October 19, Sihe Genomics announced the appointment of Dr.
Huang Yue as the Chief Translational Science Officer (CTO), responsible for the preclinical and clinical research and development of
Sihe Pharma's independent innovation antisense oligonucleic acid drug research and development project.
Dr.
Huang Yue has 22 years of experience in innovative drug R&D management, and has been responsible for the whole process of innovative drug R&D projects at MNC such as Novartis, Roche, Merck and Quintiles, as well as Simcere Pharmaceutical
, a leading pharmaceutical company in China.

Huang Yue

Hua Fengmao, CEO of Ridge Pharmaceutical, resigned

On October 20, Ridge Pharma issued an announcement that Mr.
Hua Fengmao resigned as a director, chief executive officer, special committee of the board of directors and subsidiaries of the company for personal reasons
.
It is reported that Hua Fengmao has rich experience
in investment banking and pharmaceutical industry.
He has worked in a number of investment banks, mainly responsible for corporate finance, public offerings, restructuring, mergers and acquisitions and other financial advisory work
.

Hua Fengmao

Wang Jie, vice president of Yifan Pharmaceutical, resigned

Efan Pharma announces that it has received a written resignation report
from Mr.
Wang Jie, Vice President.
After reaching a consensus with the company, Mr.
Wang Jie applied to resign as vice president of the company, and will not hold any position
in the company and its subsidiaries after his resignation.
It is worth noting that Wang Jie took up the post of vice president of Yifan Pharmaceutical in May this year, and has served for less than half a year
.

Wang Jie

Tao Weikang, deputy general manager of Hengrui Pharmaceutical, joined Qilu Pharmaceutical

Hengrui Pharmaceutical announced that Mr.
Tao Weikang applied to resign from the position of deputy general manager of the company due to personal reasons, and nominated Mr.
He Feng as the deputy general manager
of Hengrui Pharmaceutical.
It is reported that He Feng will undertake the new drug research and development and management of Shanghai Hengrui R&D Center, and become the core leading force
in the field of innovation and research and development of Hengrui Pharmaceutical.
Mr.
Tao Weikang then joined Qilu Pharmaceutical as Group Vice President and General Manager of
Qilu Global Innovative Drug R&D.

The whereabouts of Fan Xiaohu, the founder of the legendary creature, have been decided

Fan Xiaohu, who left Legend Bio at the end of March, has decided on his whereabouts and assumed the post of dean of the Institute of
Gene and Cell Therapy at Xi'an Jiaotong University.
Xiaohu Fan is the founder and former Chief Scientific Officer (CSO)
of Legendary Biologics.
In 2014, Fan Xiaohu joined GenScript Biologics as the head of the antibody protein engineering department; In 2015, the subsidiary Legend Biologics was established, focusing on CAR-T cell therapy, and Fan Xiaohu served as CSO and participated in the research and development
of cedarquiolence.

Fan Xiaohu

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.